Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

B-cell maturation antigen (BCMA)–targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Adam D., Mateos, María-Victoria, Cohen, Yael C., Rodriguez-Otero, Paula, Paiva, Bruno, van de Donk, Niels W. C. J., Martin, Thomas, Suvannasankha, Attaya, De Braganca, Kevin C., Corsale, Christina, Schecter, Jordan M., Varsos, Helen, Deraedt, William, Wang, Liwei, Vogel, Martin, Roccia, Tito, Xu, Xiaoying, Mistry, Pankaj, Zudaire, Enrique, Akram, Muhammad, Nesheiwat, Tonia, Pacaud, Lida, Avivi, Irit, San-Miguel, Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562529/
https://www.ncbi.nlm.nih.gov/pubmed/36095849
http://dx.doi.org/10.1182/blood.2022015526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562529/
https://www.ncbi.nlm.nih.gov/pubmed/36095849
http://dx.doi.org/10.1182/blood.2022015526

Ejemplares similares